Asahi Kasei has concluded a license agreement with Schering AG of Germany for the injectable formulations of fasudil. This agreement complements Schering AG’s rights to the compound’s oral formulations obtained in a separate agreement last year. Under that agreement, Schering is presently conducting U.S. clinical trials in patients with angina pectoris.
Background
With 2001 sales of around ¥1.4 billion, the injectable formulation of fasudil is commercially available in Japan under the trade name Eril® Injection S for the improvement of cerebral vasospasm following surgery for subarachnoid hemorrhage and associated cerebral ischemic symptoms. Having shown efficacy in Phase II clinical trials, Eril® Injection S has entered Phase III trials for the additional indication of acute cerebral thrombosis.
| Essentials of the agreement |
- Licensed pharmaceutical: Fasudil for injectable administration
- Licensee: Schering AG of Germany
- Scope: Exclusive development and marketing worldwide except for Japan, South Korea, China, and Taiwan
- Initial Program: Schering AG to perform clinical development in North America and Europe of fasudil’s intravenous formulation to treat patients with subarachnoid hemorrhage
|
Schering AG: Corporate profile in brief
Schering AG is a research-based pharmaceutical company. Its activities are focused on four business areas: Fertility Control & Hormone Therapy, Diagnostics & Radiopharmaceuticals, Dermatology as well as Specialized Therapeutics for disabling diseases in the fields of the central nervous system, oncology and cardiovascular system. As a global player with innovative products Schering AG aims for leading positions in specialized markets worldwide. With in-house R&D and supported by an excellent global network of external partners, Schering AG is securing a promising product pipeline. Using new ideas, Schering AG aims to make a recognized contribution to medical progress and strives to improve the quality of life: making medicine work.
For more information on Schering AG, visit their website at www.schering.de/eng
|
